Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Jul 08, 2022 1:55pm
174 Views
Post# 34811536

RE:RE:RE:RE:Another update

RE:RE:RE:RE:Another update

I hate to talk about Juniper's wife in such a dispassionate way but you could easily see her as evidence that the drug works while at the same time, given her circumstances, you would never be able to Press Release her responses as evidence of efficacy. I remember somebody talking about a conversation with the Chairwoman during the annual meeting where she said they'd seen other instances which didn't quite reach the standard of reportable data but gave them hope. So we might imagine there have been others in a similar situation to Juniper's wife. You can see this all as simply a matter of time, not great when that's what we have been giving it in heaps. 


Trogarzon wrote: I retain from this information that it's complicated and not exactly conclusive atm.   We need 30% tumor reduction to be considered a win... for now we have some regression and then some worsening.  So much for the quick price fix I guess and the OO no.2 at 2$... 

 

<< Previous
Bullboard Posts
Next >>